64cu-sar-bbn
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 9, 2022 (NCT05613842)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 64-copper
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05633160 | Phase 1/Phase 2 (Phase 2) | May 31, 2023 | Clarity Pharmaceuticals Ltd |
| NCT05407311 | Phase 2 | Sep 19, 2022 | Clarity Pharmaceuticals Ltd |
| NCT05613842 | Phase 2 | Aug 9, 2022 | Clarity Pharmaceuticals Ltd, GMP BIO Co., LTD., University of New South Wales |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Clarity Pharmaceuticals Ltd | For profit | 3 | 2 | 1 | 2022 |
| GMP BIO Co., LTD. | For profit | 1 | 0 | 1 | 2022 |
| University of New South Wales | Academic/Hospital | 1 | 1 | 1 | 2022 |
3 organizations
Page 1 / 1